

**IN THE MATTER OF  
AMANDA L. PHILLIPS**

**Respondent**

**Registration Number: T25188**

**BEFORE THE MARYLAND  
STATE BOARD OF PHARMACY**

**Case Number: 26-275**

---

**ORDER FOR SUMMARY SUSPENSION OF  
REGISTRATION TO PRACTICE AS A PHARMACY TECHNICIAN**

The Maryland State Board of Pharmacy (the “Board”) hereby **SUMMARILY SUSPENDS** the registration of **AMANDA L. PHILLIPS** (the “Respondent”), Registration Number **T25188**, to practice as a pharmacy technician in the State of Maryland. The Board takes such action pursuant to its authority under Md. Code Ann., State Government (“State Gov’t”) § 10-226(c), and Md. Code Regs. (“COMAR”) 10.34.01.12, having concluded that the public health, safety, or welfare imperatively requires emergency action.

**INVESTIGATIVE FINDINGS<sup>1</sup>**

1. At all times relevant, the Respondent was registered to practice as a pharmacy technician in the State of Maryland under registration number T25188. The Respondent’s pharmacy technician registration was initially issued on or about June 2, 2021. The Respondent’s registration expires on July 31, 2026, subject to renewal.

---

<sup>1</sup> The statements regarding the Respondent’s conduct are intended to provide the Respondent with reasonable notice of the basis for the Board’s action. They are not intended as, and do not necessarily represent, a complete description of the evidence to be offered against the Respondent in this matter.

2. At all times relevant, the Respondent was employed as a pharmacy technician at a national pharmacy chain (the “Pharmacy”)<sup>2</sup> with location in Dunkirk, Maryland.

3. On or about March 2, 2026, the Board received notification from the Pharmacy of suspected employee pilferage of controlled dangerous substances (“CDS”) at the Dunkirk store location. On or about March 19, 2026, the Board received from the Pharmacy a copy of the Drug Enforcement Agency (“DEA”) Report of Theft or Loss of Controlled Substances Form (“DEA Form 106”) reporting that the Respondent, a Pharmacy Technician at the Pharmacy, was terminated from the Pharmacy after admitting to diversion of CDS stolen from the Pharmacy.

4. In the DEA Form 106, the Pharmacy identified approximately 1300 pills that the Respondent stole from the Pharmacy, including alprazolam 0.5 mg (#160), alprazolam 1 mg (#145), alprazolam 2 mg (#14), clonazepam 0.25 mg (#225), clonazepam 0.5 mg (#200), clonazepam 1 mg (#235) and clonazepam 2 mg (#220).

5. In response, the Board initiated an investigation of the Respondent under case number 26-275.

### **Pharmacy Internal Investigation**

6. Based on information that the Respondent was vaping at the Pharmacy and was recently arrested for possession of drugs, the Pharmacy initiated an internal

---

<sup>2</sup> For confidentiality and privacy purposes, the names of individuals and facilities involved in this case are not disclosed in this document. The Respondent may obtain the names of all individuals referenced in this document by contacting the administrative prosecutor.

investigation of the Respondent. The Pharmacy's internal investigation revealed that on or about February 19, 2026, a Pharmacy District Asset Protection Leader ("DAPL") and the manager (the "Manager") of the Pharmacy's Dunkirk store interviewed the Respondent regarding the missing drugs. During the interview and in a voluntary written statement, the Respondent admitted to stealing approximately 1,300 pills of alprazolam and clonazepam from the Pharmacy beginning towards the end of 2024. The Respondent admitted to stealing the drugs by hiding them in her clothes and later giving the drugs to a friend. The Respondent further admitted that the total loss for the Pharmacy was approximately \$1,315.

7. At conclusion of the interview, the Respondent was immediately suspended and later terminated from her employment at the Pharmacy. The Pharmacy also reported the theft to the local county police department.

### **CONCLUSIONS OF LAW**

Based on the foregoing investigative findings, the Board concludes, as a matter of law, that the public health, safety, or welfare imperatively requires emergency action in this case, pursuant to Md. Code Ann., State Gov't § 10-226(c)(2) and COMAR 10.34.01.12.

### **ORDER**

Based on the foregoing Investigative Findings and Conclusions of Law, by a majority vote of the Board, it is hereby:

**ORDERED** that pursuant to the authority vested in the Board by Md. Code Ann., State Gov't § 10-226(c)(2), the registration to practice as a pharmacy technician in the State of Maryland issued to the Respondent, **AMANDA L. PHILLIPS**, Registration Number **T25188**, is hereby **SUMMARILY SUSPENDED**; and it is further

**ORDERED** that the Respondent is prohibited from practicing as a pharmacy technician in the State of Maryland; and it is further


**ORDERED** that the Respondent shall immediately return all registrations to the Board; and it is further

**ORDERED** that the Respondent has the opportunity to appear before the Board for a post-deprivation show cause hearing. A request for a post-deprivation show cause hearing must be made to the Board in writing **WITHIN THIRTY (30) DAYS**; and it is further

**ORDERED** that if the Respondent does not request a post-deprivation show cause hearing in writing within thirty (30) days, or if the Respondent requests a post-deprivation show cause hearing but fails to appear when scheduled, the Respondent's registration will remain **SUSPENDED**; and it is further

**ORDERED** that this **ORDER FOR SUMMARY SUSPENSION** is a **PUBLIC DOCUMENT** pursuant to Md. Code Ann., Gen. Prov. §§ 4-101 *et seq.*

6-16-24  
Date

  
\_\_\_\_\_  
Deena Speights-Napata, M.A.  
Executive Director  
Maryland Board of Pharmacy